Pei Y, Wang B, Chen S
Department of Gastroenterology, Beijing Friendship Hospital, Capital University of Medical Sciences.
Zhonghua Nei Ke Za Zhi. 1995 Sep;34(9):606-8.
To evaluate the efficacy of a second generation acid pump inhibitor-lansoprazole (L) a controlled clinical trial in 72 patients of duodenal ulcer was carried out with omeprazole (O) as control. The results showed that the ulcer healing rate after 4-week treatment was 97.4% in lansoprazole group and 91.2% in omeprazole, while the effective rate was 100% and 97.1% respectively (P > 0.05). Ulcer related pain was relieved more quickly in lansoprazole group. The pain relief rate after treatment of 3 days was different significantly between the two group, being 74.3% (L) and 51.6% (O) respectively (P < 0.05). No marked side-effect was observed in lansoprazole group. It is shown that lansoprazole is effective and safe for treatment of duodenal ulcer.
为评估第二代质子泵抑制剂兰索拉唑（L）的疗效，以奥美拉唑（O）为对照，对72例十二指肠溃疡患者进行了一项对照临床试验。结果显示，兰索拉唑组4周治疗后的溃疡愈合率为97.4%，奥美拉唑组为91.2%，而有效率分别为100%和97.1%（P>0.05）。兰索拉唑组溃疡相关疼痛缓解更快。两组治疗3天后的疼痛缓解率差异显著，分别为74.3%（L）和51.6%（O）（P<0.05）。兰索拉唑组未观察到明显副作用。结果表明，兰索拉唑治疗十二指肠溃疡有效且安全。
